论文部分内容阅读
对７例尿毒症患者血液透析前后体内地高辛水平做了动态观察。用放射免疫法测定地高辛浓度，结果表明：（１）０．１２５ｍｇ·ｑｄ－１口服用药法安全可靠，服药６ｈ后的血清地高辛浓度皆在有效范围内；（２）透析末期及结束后的３ｈ（Ｐ＜０．０５）、５ｈ（Ｐ＜０．０１）、７ｈ（Ｐ＜０．０５）血清地高辛浓度产生“反跳”，平均升高（０．１７±０．０４）×１０－９ｍｏｌ·Ｌ－１；（３）与对照组相比，血液透析对地高辛吸收相和分布相无显著性影响（Ｐ＞０．０５）；（４）次日给药比ｄ３给药血清地高辛浓度平均升高（０．１３±０．０６）×１０－９ｍｏｌ·Ｌ－１；（５）透析液中无地高辛存在；（６）其中３例统计得出由尿排泄的地高辛是给药量的１３．１７％±３．５６％，为正常人排出量的１４．３％。
Seven patients with uremia before and after hemodialysis in vivo digoxin level made a dynamic observation. The radioimmunoassay was used to determine the concentration of digoxin. The results showed that: (1) 0.125 mg · qd-1 oral administration was safe and reliable, and the concentration of serum digoxin after 6 hours was within the effective range; (2) At the end of 3h (P <0.05), 5h (P <0.01), 7h (P <0.05) serum digoxin concentration “rebound”, with an average increase of 0.17 ± 0. 04) × 10-9mol·L-1; (3) Compared with the control group, hemodialysis had no significant effect on the absorption and distribution of digoxin (P> 0.05); (4) Compared with d3 administration, serum digoxin concentration increased by an average of 0.13 ± 0.06 × 10-9mol·L-1. (5) There was no digoxin existed in dialysis solution. (3) Digoxin excreted by the urine was 13.17% ± 3.56% of the dose, which was 14.3% of the normal person’s discharge.